A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

Summary

To evaluate the safety and efficacy of Tai Ai(Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.

Timeline

Start

2020-04-13

Primary completion

2021-05-20

Completion

2021-05-20

Publications

• Pei J, Xu X, Huang R, Sun X, Zhang J, Chen X, Yao L, Zhang H, Shao L, Li Y. Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study. BMC Nephrol. 2025 Dec 17;27(1):92. doi: 10.1186/s12882-025-04708-w.
• Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.

Drugs

Indications